Pifusertib (TAS-117) hydrochloride is an effective, selective, orally active allosteric Akt inhibitor (IC50 values of 4.8, 1.6, and 44 nM for Akt1, Akt2, and Akt3, respectively); it exhibits anti-myeloma activity and enhances proteasome inhibitor-induced lethal endoplasmic reticulum stress; it induces apoptosis and autophagy.